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Ofatumumab is a unique monoclonal anti-
body that targets a distinct small loop
epitope on the CD20 molecule. Preclinical
data show that ofatumumab is active
against B-cell lymphoma/chronic lympho-
cytic leukemia cells with low CD20-
antigen density and high expression of
complement inhibitory molecules. In a
phase 1/2 trial evaluating safety and effi-
cacy of ofatumumab in relapsed or refrac-
tory follicular non-Hodgkin lymphoma (FL)
grade 1 or 2, 4 dose groups of 10 patients
received 4 weekly infusions of 300, 500,
700, or 1000 mg. Patients had a median of
2 prior FL therapies and 13% had elevated
lactate dehydrogenase. No safety con-
cerns or maximum tolerated dose was
identified. A total of 274 adverse events
were reported; 190 were judged related to
ofatumumab, most occurring on the first
infusion day with Common Terminology
Criteria grade 1 or 2. Eight related events
were grade 3. Treatment caused immedi-
ate and profound B-cell depletion, and
65% of patients reverted to negative BCL2
status. Clinical response rates ranged
from 20% to 63%. Median time to progres-
sion for all patients/ responders was 8.8/
32.6 months, and median duration of re-
sponse was 29.9 months at a median/
maximum follow-up of 9.2/38.6 months.
Ofatumumab is currently being eval-
uated in patients with rituximab-refractory
FL. This trial was registered at www.
clinicaltrials.gov as #NCT00092274. (Blood.
2008;111:5486-5495)
© 2008 by The American Society of Hematology
Introduction
The successful use of monoclonal antibodies (mAb’s) in the
treatment of human disease has steadily been growing the last
decade. Rituximab, a human-mouse chimeric anti-CD20 antibody,
was approved in 1997 as the first mAb for antilymphoma therapy. It
was introduced as monotherapy and is now most commonly used in
combination with chemotherapy for first and subsequent lines of
therapy in follicular non-Hodgkin lymphoma (FL) followed by
maintenance antibody treatment.1-10 However, a subgroup of pa-
tients does not respond, and in patients with initial response early
relapses occur, indicating rituximab resistance. This indicates a
clear unmet need to explore alternative antibodies non-cross
resistant to rituximab, such as ofatumumab (HuMax-CD20; Gen-
mab, Copenhagen, Denmark), which is a fully human CD20 mAb
with a potential low incidence of human-antihuman antibody
(HAHA) formation.
Ofatumumab targets a novel epitope of the CD20 molecule on
B cells and releases only very slowly from the target compared with
rituximab. The antibody is generated via transgenic mouse and
hybridoma technology and produced in a recombinant murine cell
line (NS0) using standard mammalian cell cultivation and purifica-
tion technologies.11 Compared with rituximab, ofatumumab has
similar antibody-dependent cellular cytotoxocity but delivers stron-
ger complement-dependent cytotoxicity even to lymphoma cells
with a low CD20 antigen density and a high number of CD55 and
CD59 complement inhibitory molecules present in the cell mem-
brane. In laboratory tests, ofatumumab was found to be superior to
rituximab with respect to its ability to induce lysis in different
B-cell lines (eg, SU-DHL-4, Daudi, and Raji) and to kill fresh
B-chronic lymphocytic leukemia (B-CLL) cells resistant to ritux-
imab.11,12 In animal studies, ofatumumab has been shown to deplete
B cells effectively. The depletion of B cells from peripheral blood
and lymph nodes of cynomologus monkeys lasted longer than the
depletion induced by rituximab.13 Ofatumumab has also proved
therapeutic against Daudi cell growth in an in vivo mouse
xenograft model with maximum effect at 0.5 mg/kg intraperitoneal-
ly.14 These data project that ofatumumab has the potential to treat
B-cell malignancies with low CD20 and high CD55 and CD59
expression, such as B-CLL and rituximab-refractory FL.
This article presents results from a phase 1/2 clinical trial with
single-agent ofatumumab in relapsed or refractory FL in a dose-
escalating manner, evaluating safety, efficacy, and pharmaco-
kinetics (PK).
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Methods
Objectives
The purpose of this open-label, multicenter, phase 1/2 trial was to assess the
safety, tolerability, and efficacy of escalating doses of ofatumumab in
patients with relapsed or refractory FL grade 1 or 2. PK evaluation was
included as a secondary objective.
Patient population
The patients enrolled in the trial were 18 years of age or older with relapsed
or treatment-refractory FL grade 1 or 2, defined according to the World
Health Organization lymphoma classification. Patients should have pro-
gressed after completion of the previous FL treatment, which had induced
complete response (CR), complete response unconfirmed (CRu), or partial
response (PR) for at least 3 months, or be refractory to any FL treatment for
at least 6 months. Prestudy eligibility criteria also included verification of
an excisional lymph node biopsy (original or new) to be CD20 FL by
central pathology review (BARC, Ghent, Belgium) and with computerized
tomography (CT) showing 2 or more clearly demarcated lesions with a
largest diameter more than or equal to 1.5 cm, or one clearly demarcated
lesion with a largest diameter more than or equal to 2.0 cm. No lymphoma
treatment was permitted up to 4 weeks before recruitment. The exclusion
criteria included suspicion of transformation to aggressive lymphoma,
unless a new biopsy confirmed FL without transformation, more than
10  109/L circulating CD20 lymphoma cells, platelets 75  109/L,
neutrophils less than 1.5 109/L, serum creatinine more than 1.5 times
upper normal limit (unless normal creatinine clearance), total bilirubin
more than 1.5 times upper normal limit (unless resulting from liver
involvement of lymphoma), alanine aminotransferase or alkaline phospha-
tase more than 2.5 times upper normal limit (unless resulting from liver
involvement of lymphoma), known or suspected central nervous system
lymphoma, past or current malignant disease (except for cervical carci-
noma stage 1B or less, noninvasive basal cell and squamous cell skin
carcinoma, breast cancer with CR 10 years, malignant melanoma with
CR  10 years, other cancer diagnosis with CR for  5 years), severe
uncontrolled, nonmalignant disease (eg, cardiac, pulmonary, neurologic
disease), previous treatment with rituximab resulting in less than partial
response or duration of response less than 6 months, treatment with
rituximab within 6 months before inclusion, more than 2 previous treatment
cycles with rituximab regardless of response, prior autologous or allogeneic
stem cell transplantation, and previous radioimmunotherapy.
Ethical approval was obtained from the independent Ethics Committees
and Institutional Review Boards of each site before trial initiation. All
patients gave their written informed consent before enrollment.
The trial was performed in accordance with the Declaration of Helsinki
and good clinical practice and was monitored by an independent Data
Monitoring Committee.
Ofatumumab antibody
Ofatumumab is a fully human IgG1 kappa anti-CD20 mAb produced with a
recombinant murine cell line (NS0) using standard mammalian cell
cultivation and purification technologies. The NS0 cell line has been
transfected with a gene search vector carrying the antibody genes derived
from the human anti-CD20 hybridoma cell line (2F2) generated via
transgenic mouse technology.11 The molecular weight of the antibody is
approximately 149 kDa as determined by mass spectrometry. Ofatumumab,
formulated at 20 mg/mL in an isotonic buffer of 30 mM of sodium citrate
and 100 mM sodium chloride adjusted to a pH 6.5 with citric acid, was
administered intravenously after dilution in a sterile and pyrogen-free saline
solution. Ofatumumab was supplied by Genmab.
Treatment plan
Patients were divided into 4 dose groups receiving 4 weekly intravenous
infusions of 300 mg, 500 mg, 700 mg, or 1000 mg of ofatumumab in
500 mL normal sterile saline. The 700-mg dose reflects the rituximab dose
of 375 mg/m2. In addition, 2 lower doses and 1 higher dose were included.
A fixed-dose regimen was chosen as a great variability of serum concentra-
tion was seen in the pivotal study for rituximab dosed per square meter.15
Ten patients in succession were enrolled at each dose level.
Ofatumumab was administered as 4 weekly intravenous infusions by an
infusion pump with an in-line filter. Premedication with oral acetaminophen
and intravenous antihistamine was given to all patients before each
infusion. The use of concomitant glucocorticosteroids is described in the
following paragraph.
Patients were assigned in consecutive order starting at the lowest dose
level (300 mg). Dose escalation took place after the 10th patient had been
allocated, the first 3 patients had received all 4 infusions and 1 week of
follow-up, the sixth patient had received the first infusion and 1 week of
follow-up, and less than 2 cases of dose-limiting toxicity (DLT) were
observed in the first 6 patients. DLT was defined as: occurrence of a
treatment-related adverse events (AEs) with intensity more than or equal to
grade 3 at the day of infusion despite treatment with glucocorticosteroids, or
any treatment-related nonhematologic AE with intensity more than or equal
to grade 3 on noninfusion days, or any treatment-related hematologic AE
with intensity more than or equal to grade 4 on noninfusion days. At the
initiation of the trial, the infusion was started at 25 mL/hour during the first
hour and increased to a maximum rate of 400 mL/hour if well tolerated.
Subsequent infusions were started at 50 mL/hour if no infusion-related AEs
were recorded at the previous infusion. Concomitant intravenous glucocor-
ticosteroids (equivalent to 50 mg of prednisolone) were used only when
infusion-related AEs with intensity more than or equal to grade 3 had been
reported at the previous infusion or if infusions took more than 6 hours
because of infusion-related AEs.
Evaluation and trial endpoints
Baseline evaluation included disease history and previous medication,
current stage of disease including signs and symptoms, physical examina-
tion, laboratory assessments, CT scans with contrast of the neck, thorax,
abdomen, and pelvis, bone marrow biopsy, and diagnostic FL verification
(CD20) from the original or a new excisional lymph node biopsy. Imaging
modality and parameters were to remain consistent across all visits for any
given patient. Baseline CT scans were initially evaluated by the site to
ensure that the needed quality of the images was attained and to verify
compliance with the inclusion criteria. Subsequently, a central reevaluation
of all CT scans was conducted (Perceptive Informatics, Berlin, Germany).
Safety evaluations, including AEs, vital signs, laboratory safety assess-
ments (hematology, clinical chemistry), and complement (CH50) measure-
ments by liposome immunoassay were performed weekly throughout the
treatment period. CD19 and CD20 B cells, T-cell subsets (CD3, CD4,
and CD8), and natural killer (NK) cells (CD16/56 cells) were recorded
using flow cytometry after 1, 4, 11, 19, and 26 weeks and after 9 and
12 months. Titers of HAHA in serum were quantified by an enzyme-linked
immunosorbent assay at week 19 and month 12. AEs were categorized and
graded according to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0.16 AEs, DLT, and the percentage of
patients developing HAHA were safety endpoints together with laboratory
biochemistry and hematology data. AEs were used to identify the maximum
tolerated dose (MTD) defined as the dose level below the dose level in
which any of the following occurred: one treatment-related, fatal, life-
threatening or permanently disabling serious AE (SAE), 2 cases of DLT in
the first 6 patients at one dose level within 1 week of follow-up of the sixth
patient after first dose, or 3 cases of DLT. A definition of DLT is given in
“Treatment plan.”
Efficacy
The primary efficacy endpoint of the study was clinical response over the
period from screening to week 19. The overall tumor responses from
screening to week 11, 19, and 26 were secondary efficacy endpoints
together with B-cell depletion in peripheral blood as percentage change in
CD19 and CD20 cells, percentage of patients converting from BCL2-
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positive to BCL2-negative in the peripheral blood, time to progression,
duration of response, and time to next anti-FL therapy.
Evaluation of disease was performed by physical examination (enlarged
lymph nodes, hepatomegaly, and splenomegaly) and screening for B
symptoms (night sweats, weight loss, or fever) at weeks 4, 7, 11, 19, and 26,
and months 9 and 12, CT scans with contrast of the neck, thorax, abdomen,
and pelvis at weeks 11, 19, and 26, and a bone marrow biopsy at weeks 19
and 26, if initially positive. Response to treatment was analyzed using
standard outcome measures for clinical trials (CR, CRu, PR, stable disease
[SD], and progressive disease [PD]) as defined by the International
Workshop Response Criteria for non-Hodgkin lymphoma.17 After month
12, unvalidated progression data were collected directly from sites in
periodically faxed forms. Clinical response was defined as best overall
tumor response of CR, Cru, or PR. Lymphoma burden was estimated by the
sum of the product of the largest perpendicular diameters (SPD) of the
(maximally) 6 largest lesions (indicator lesions) based on CT scans.
Changes in SPD from baseline to weeks 11, 19, and 26 were followed.
Quantification of CD19 and CD20 cells in the peripheral blood was
performed on ethylenediaminetetraacetic acid blood samples using flow
cytometry at screening, weeks 1, 4, 11, 19, and 26, and months 9 and 12.
BCL2 conversion at week 19 was assessed in the peripheral blood by the
detection of t(14;18) translocation using a polymerase chain reaction (PCR)
detection strategy.18
PK sampling was performed on the days of treatment (days 0, 7, 14, and
21), and on days 1, 3, 5, 22, 25, 28, and 49. The concentration of
ofatumumab was determined in serum using a sandwich immunoassay.
Ninety-six-well enzyme-linked immunosorbent assay plates were coated
with idiotype specific mouse monoclonal antiofatumumab antibody and
subsequently incubated with the patient’s serum and Fc specific antihuman
IgG1 antibodies. The latter are enzyme-labeled antibodies (horseradish
peroxidase), which function as detection probes. Subsequently, detection
was performed by adding azino benzothiazoline sulphonic acid substrate
resulting in a color development, which can be measured at 405 nm. The
concentration of ofatumumab can be read from a standard curve by plotting
the optical density as a function of the ofatumumab concentration. A
4-parameter log-logistic curve-fitting model was used for this purpose.
Statistical methods
No formal sample size calculation was performed. The planned number of
patients was considered adequate to meet the primary objective of the study
and is in agreement with regulatory guidance for this type of trial. The
efficacy analysis was performed for the full analysis population (ie, all
patients treated). Two-sided 95% confidence intervals (CIs) for clinical
response were calculated using exact binomial distribution methods.
Relationships between clinical response and other parameters were esti-
mated using the Spearman’s nonparametric rank correlation coefficient and
tested by using 2-sided Wilcoxon nonparametric tests. The influence of
possible explanatory variables on clinical response was investigated using
logistic regressions. Kaplan-Meier analyses, including estimations of
medians, were performed for time to progression, duration of response, and
time to next anti-FL therapy, which was at the discretion of each individual
clinical investigator. All tests were 2-sided and performed on the 5%
significance level. No multiplicity adjustments were made.
Results
Patients
Between April 2004 and November 2005, 40 patients with relapsed
or refractory FL were enrolled into the trial at the 14 trial sites.
There were 20 male and 20 female, all white. Median age was
58.5 years (range, 34-75 years). Median time from original FL
diagnosis to entry into the trial was 4.5 years (range, 0.7-17.1 years). The
median number of all prior treatment regimens was 2 (range, 1-8).
Thirteen percent (5 of 40) of patients had elevated lactic dehydrogenase
at baseline, and the majority of patients were Ann Arbor stage IIIA
(30%) or IVA (35%). Previous rituximab treatment (monotherapy or in
combination with chemotherapy) was received by 15 patients. Four of
these patients were refractory to rituximab treatment but were not
thought to impact the efficacy assessment and were therefore not
excluded from the trial population. Baseline characteristics of the patient
populations at each dose level are presented in Table 1. All 40 patients
were evaluated for safety. Of the 40 patients who received ofatumumab
treatment, 37 were considered assessable for efficacy. One patient was
excluded because of incomplete treatment. Two patients were not
evaluable for clinical response as review of the CT scans showed
absence of measurable indicator lesions at screening. Glucocorticoste-
roids were administered to 9 of 40 patients during the trial.
Treatment
Thirty-nine of 40 patients received 4 weekly courses of ofatu-
mumab, whereas one patient was withdrawn after only one infusion
because of an SAE. Glucocorticosteroids were only administered
before 36 of 157 (23%) of the infusions.
Table 1. Patient demographics and pretreatment characteristics
Dose 300 mg 500 mg 700 mg 1000 mg
No. of patients 10 10 10 10
Median age, y (range) 58 (47-75) 64 (36-66) 56 (34-73) 56 (39-73)
Sex, male/female 5/5 5/5 5/5 5/5
Median body surface area, m2 (range) 1.9 (1.8-2.1) 2.0 (1.7-2.1) 2.0 (1.5-2.5) 1.8 (1.5-2.5)
No. of prior treatment regimens, median (range) 2 (1-5) 1.5 (1-4) 2 (1-4) 3 (1-8)
No. of patients with complete response to prior 7 8 2 6
treatment regimens
No. of patients previously treated with rituximab 5 2 3 5
Ann Arbor stage
IA 0 0 1 1
IIA 3 1 2 1
IIIA 2 4 2 4
IVA 5 4 2 3
IVB 0 1 3 1
No. of lesions, median (range) 2.5 (0-4) 3 (1-5) 2 (1-3) 2 (1-4)
Sum of the products of the largest perpendicular 1275 (0*-13 764) 2568 (510-6723) 1767 (817-6135) 2042 (288-8134)
diameters, mm2, indicator lesions (range)
*Two patients had no indicator lesions.
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The median duration of the first infusion was 4.20 hours,
ranging from 2.30 to 13 hours, and the median duration of the
subsequent 3 infusions was 2.30 to 3.10 hours. The duration of the
first infusion was, in all dose groups, longer than the duration of
succeeding infusions (Figure 1), partly because of the higher incidence
of infusion-related reactions with the first dose (Figure 2).
Safety
All 40 enrolled patients were evaluated for safety. One patient in
the 500-mg group experienced an SAE (laryngeal edema, grade 3)
during the first infusion. The patient recovered and was withdrawn
from further treatment and from the trial. The event was judged to
be related to ofatumumab treatment and was recorded as a DLT
evaluated by the Data Monitoring Committee. Twenty patients
withdrew from the study because of deterioration of study disease.
Two patients withdrew because of stem cell harvesting. One
patient’s data were censored at the time of stem cell transplantation,
whereas the other patient was censored at the last visit in the trial.
The 23 withdrawn patients were distributed among dose groups as
follows: 3, 7, 8, and 5 in the 300-mg, 500-mg, 700-mg, and
1000-mg dose groups, respectively. A total of 274 AEs were
reported in 40 patients and 190 (70%) were judged to be related to
ofatumumab (Table 2). Ninety-five percent were of grade 1 or 2 in-
tensity. The most frequent AEs were within the system organ class
“general disorders and administration site conditions” (pyrexia,
chills, and fatigue), “respiratory, thoracic, and mediastinal disor-
ders” (dyspnea, pharyngolaryngeal pain, and cough), and “skin and
subcutaneous tissue disorders” (pruritus, rash, and urticaria). Other
frequent AEs were headache, hypotension, and nausea. The majority of
patients (38 of 40) experienced AEs on an infusion day, and more than
half (55%) of the reported AEs had onset before second infusion. As
shown in Figure 2, 90% to 100% of patients reported AEs on the day of
first infusion, whereas only 30% or fewer patients reported AEs on the
second, third, and fourth infusions. Usually, the infusion-related AEs
occurred within the first few hours of starting the ofatumumab infusion,
with the most common symptoms being transient chills rash, pruritus,
pyrexia, and urticaria. Infusion-related AEs prolonged especially the
duration of the first infusion (Figure 1). Of the 274 AEs, 13 events were
CTC grade 3 (Table 2). One case of ovarian epithelial cancer (cystadeno-
carcinoma mucinosum grade 1) was assessed as unrelated to ofatu-
mumab, and the patient fully recovered after surgery. Eight grade 3
events in 7 patients were judged to be related to ofatumumab, which was
2 events of dyspnea and 1 event of hypoxia, laryngeal edema, throat
tightness, pruritus, rash, and abdominal pain, respectively. All occurred
on the first day of infusion and all fully recovered. No relationship
between dose and number or severity of AEs was observed (Table 2).
After the end of the trial, 2 SAEs with fatal outcome were reported; one
patient died of disease progression 5 months after final treatment, and
one patient died of sepsis resulting from peritonitis 17 months after the
final treatment, which was after subsequent treatment for FL. Two grade
4 SAEs were also reported after the end of the trial, one leucocytopenia
secondary to treatment with chlorambucil resulting from FL progression
and one additional case of mucinous cystadenocarcinoma (endometrioid
adenocarcinoma grade 1) with no signs of relapse 6 months after the
completion of chemotherapy with taxol and carboplatin. The patient had
undergone repeated ultrasound examinations and in retrospect the tumor
could have been identified before the treatment with ofatumumab. One
case of ductal carcinoma grade 2 with high-grade ductal carcinoma in
situ was also reported after the end of the trial. Mastectomy with axillary
clearance was performed. Final outcome is pending. The investigator
assessed the event to be related to ofatumumab but also to hormone
replacement therapy.
Hematologic toxicity consisted of one episode of grade 2
thrombocytopenia, which was considered clinically relevant and
was consequently reported as an AE. In addition, 7 events of
neutropenia (6 grade 1 or 2 and 1 grade 3) and 6 grade 1 events of
thrombocytopenia were recorded, which did not require clinical
intervention. The majority of the grade 1 or 2 neutropenias
(1.0-1.6 109/L) occurred at one visit in weeks 11 to 26 and were
resolved at the following visit. The grade 3 neutropenia (0.8 109/
L) occurred in week 19 and was resolved the following visit (week
26). The sporadic thrombocytopenias occurred from screening to
week 26 and were in most cases resolved before or at week 26.
Based on AEs, the MTD was not identified for any patient.
Infections
Twenty infectious AEs were reported in 13 patients with 2 events of
grade 3 infections reported as SAEs (one urinary tract infection and
one neutropenic sepsis occurring 3 months after cessation of trial
drug; Table 2). The 2 events were assessed as unrelated to
ofatumumab by the investigators, and the patients fully recovered
after treatment with ciproxin and flucloxacillin/tazocin, respec-
tively. Eighteen infections were grade 1 or 2: upper respiratory tract
infection (11), urinary tract infection (2), herpes simplex (1),
candidiasis (2), and pneumonia (2) and were all assessed as
unrelated to ofatumumab by the investigators. Distribution of
infections among dose groups was as follows: 300 mg (5 events),
500 mg (0 events), 700 mg (3 events), and 1000 mg (5 events).
Figure 1. Duration of infusions.
Figure 2. Adverse events on infusion days.
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Serum chemistry
No significant changes in serum chemistry were observed.
Immunology
Mean serum IgA and IgG levels remained stable within the normal
range. Mean serum IgM level was below normal at screening and
tended to decrease throughout the study. Thus, the median IgM
concentrations across dose groups decreased from 0.52 g/L, at
baseline to 0.41 g/L at week 26. No significant changes in serum
complement levels (CH50) were observed. No significant changes
in T-cell counts (CD3, CD4, and CD8) and NK-cell counts
(CD16/56 cells) were observed. One patient had a borderline
(8-fold) increase in HAHA at week 12. At month 12, the patient
was tested negative for HAHA. No safety concerns were raised
from any additional safety parameters monitored.
Efficacy
Clinical responses over the period from screening to week 19 were
obtained in all dose groups with response rates of 63%, 33%, 20%,
and 50% with 300 mg, 500 mg, 700 mg, and 1000 mg, respectively.
From week 19 to week 26, one additional responder, in the
1000-mg dose group, was seen. Best clinical responses from
screening to week 26 for evaluable and intention to treat patients
are shown in Table 3. In a subgroup of 14 evaluable patients
previously treated with rituximab, best clinical response was 64%
across dose groups (Table 3). Of the 4 patients refractory to
rituximab, 3 actually responded to ofatumumab treatment (one CR,
one CRu, and one PR).
Immediate, profound, and long lasting B-cell depletion (both
CD19 and CD20) was observed in all dose groups. The level
remained nearly undetectable until approximately 6 to 10 months
after treatment, followed by a slow recovery (Figures 3). Changes
in SPD from baseline are shown in Figure 4. Clinical responses
were seen at week 11 for 81% (13 of 16) of responders.
BCL2 conversion in the blood from positive to negative was
recorded in all dose groups, with a 65% conversion rate in
evaluable patients across dose groups. Only 4 of the reverted
patients responded to treatment.
The relationship between clinical response over the period from
screening to week 19 and demographic, baseline characteristics,
drug administration, and PK parameters was investigated using
Table 2. Adverse events
300 mg (N  10) 500 mg (N  10) 700 mg (N  10) 1000 mg (N  10) Total (N  40) Related
Total no.
AEs 80 44 72 78 274 190
AEs reported on any infusion day 49 30 37 43 159 152
AEs on first infusion day 41 24 34 35 134 132
SAEs 3 1 1 2 7 1
Total no. of AEs > grade 3 (no. of patients)* 6 (4) 1 (1) 3 (3) 3 (2) 13 (10) 8 (7)
Dyspnea 2 1 3 2
Hypoxia 1 1 1
Laryngeal edema 1 1 1
Throat tightness 1 1 1
Neutropenic sepsis 1 1
Urinary tract infection 1 1
Pruritus 1 1 1
Rash 1 1 1
Abdominal pain 1 1 1
Ovarian epithelial cancer 1 1
Hydronephrosis 1 1
AE indicates adverse event; N, number of subjects exposed to trial drug.
*Only treatment-emergent AEs are presented.
Table 3. Best objective clinical responses from screening to week 26
300 mg 500 mg 700 mg 1000 mg Total
No. of patients (all/previously treated with rituximab) 8*/4* 10†/2 10/3 10/5 38†/14
CR 4/3 1/0 5/3
Cru 1/1 1/0 2/1
PR 2/0 2/1 5/4 9/5
SD 3/0 6/2 6/1 3/1 18/4
PD 2/1 1/0 3/1
Clinical response (all/previously treated with rituximab) 5/4 3/0 2/1 6/4 16/9
Evaluable patients 63% 33% 20% 60% 43%
95% CI (25%-92%) (8%-70%) (3%-56%) (26%-88%) (27%-61%)
Intention to treat (ITT) 63% 30% 20% 60% 42%
95% CI (25%-92%) (7%-65%) (3%-56%) (26%-88%) (26%-59%)
Patients previously treated with rituximab 100% 0% 33% 80% 64%
95% CI (40%-100%) (1%-91%) (28%-100%) (43%-95%)
CR indicates complete response; Cru, complete response unconfirmed; PR, partial response; SD, stable disease; PD, progressive disease; and CI, confidence interval.
*Two patients had no indicator lesions.
†One patient was withdrawn before assessment (considered as a nonresponder in ITT).
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univariate logistic regressions. No statistically significant relation-
ships on the 5% level were found for the following parameters: age,
sex, body weight, body surface area, body mass index, Ann Arbor
stage, duration of FL, time from latest diagnostic biopsy, number of
prior anti-FL treatments, time from latest anti-FL treatment, relapse
to previous anti-FL treatment, best response to prior anti-FL
treatment, previously treated with rituximab, number of indicator
lesions at screening, SPD at screening, lactic dehydrogenase,
hemoglobin, BCL2, BCL2 conversion, total amount of dose
administered, glucocorticoids during trial, area under the curve
(AUC), maximum concentration (Cmax), volume of distribution
(Vz), terminal half-life (T1/2), clearance (CL), and ofatumumab
concentration at week 7.
Based on Kaplan-Meier estimates at a median/maximum
follow-up of 9.2/38.6 months, the median time to progression
(TTP) for all patients was 8.8 months (95% CI, 5.4-20.0
months), the median TTP for responders was 32.6 months (95%
CI, 22.4-38.6 months), and the median duration of response was
29.9 months (95% CI, 19.7-36.1 months). Four patients who
have not progressed yet are still in follow-up. Median time to
next anti-FL therapy was not reached during the study period
(Figure 5).
Pharmacokinetics
Serum concentrations of ofatumumab increased throughout the
treatment course. T1/2, AUC, and Cmax of the antibody signifi-
cantly increased from the first to the fourth dose simultaneously
with a significantly decreased CL. At the fourth infusion, a
statistically significant difference between genders was ob-
served in time to maximum concentration, and only men showed
a statistically significant change in Cmax between the first and the
fourth infusion. The reason for this gender difference is not
known. Values for CL and T1/2 did not indicate dose-dependent
PK for either of the 2 periods. A more than proportional increase
in AUC with dose was observed, suggesting nonlinear PK.
Serum concentrations in the individual dose groups are shown in
Figure 6. A summary of PK after the fourth dose is presented in
Figure 3. Individual CD19 B cells in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. Red triangles represent days of ofatumumab infusions.
Written values in the top of panels B and C are outliers. One patient in the 500-mg group (B) was withdrawn at visit 2; hence, data from 9 patients only are presented. The
median CD19 count at baseline was 85  106/L (range, 7-939). Most patients had a profound depletion of CD19 cells after the first infusion lasting 6 to 10 months followed by
a slow gradual recovery.
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Table 4. The median T1/2 ranged from 303 to 567 hours after the
fourth dose. A correlation between exposure (AUC and Cmax)
and clinical response to treatment at weeks 19 and 26 was not
found. For other PK parameters (T1/2, Vz, CL), correlation to
responses was only found for clinical response at week 26 and
T1/2 and CL (P  .05, 2-sided Wilcoxon nonparametric test).
Discussion
Although new therapies alone and in combination with old
therapies have demonstrated an improvement in treatment outcome
in FL, new treatment modalities with improved toxicity profile and
even better responses are needed. Ofatumumab has demonstrated a
higher potency and a longer duration of efficacy than rituximab in
several preclinical model studies and even kills rituximab refrac-
tory B cells, indicating a different mechanism of action that could
offer an advantage in the clinic.
Results from this first in human trial of ofatumumab in
patients with relapsed or refractory FL have revealed a favorable
safety profile of the agent. One patient experienced a related
SAE (laryngeal edema) during the first infusion of 500 mg of
ofatumumab and was withdrawn from the study. No stopping
rules were met, and the MTD was not reached. Forty patients
reported a total of 274 AEs; 95% were of grade 1 or 2 intensity,
the most frequent being pyrexia, chills, pruritus, and fatigue.
Thirteen (5%) AEs were grade 3 or above. Ofatumumab was
judged to be related to 190 (70%) of the AEs, 8 of grade 3. The
majority of patients (37) showed AEs in connection with the first
infusion, whereas only 30% of patients reported events during
the second, third, or fourth infusion. Usually, the infusion-
related events occurred within the first few hours of the
ofatumumab infusion, with the most common symptoms being
transient chills, rash, pruritus, pyrexia, and urticaria, probably
reflecting signs of cytokine release. In the present trial, premedi-
cation did not a priori include glucocorticosteroids, which
probably could have prevented some of the infusion-related
AEs. Glucocorticosteroids were only used in connection with
23% of infusions. Only one hematologic nonrelated event of
grade 2 thrombocytopenia was considered clinically relevant
Figure 4. Individual change in SPD from baseline in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. Two patients in the 300-mg group (A) were
without indicator lesions; hence, data from 8 patients only are presented. One patient in the 500-mg group (B) was withdrawn at visit 2; hence, data from 9 patients only are
presented. Bold lines represent clinical responders. One patient in the 1000-mg group (D) showed less than 50% reduction in the SPD at week 11 and 19 but was considered as
a nonresponder as a confirmational lymph node biopsy was positive.
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and reported as an AE. Infectious AEs occurred in 33% of
patients, including 2 patients having a grade 3 infection assessed
as unrelated to ofatumumab treatment by the investigators.
Evaluation of vital sign measurements, serum chemistry, and
whole blood counts revealed no safety issues of clinical concern
with ofatumumab infused at 4 doses up to 1000 mg. The nature
and timing of the AEs are expected in patients with large tumor
masses exposed to mAb’s. The MTD of ofatumumab is still
unknown, as is the optimal dose.
As expected, rapid, efficient, and sustained (6-10 months)
B-cell depletion was observed in the blood in all dose groups,
reflecting the potent cytolytic activity of the antibody. Despite this,
minimal changes in serum IgM concentrations, and no clinically
significant changes in serum complement, T cells, T-cell subsets,
and NK cells were observed.
Objective responses were achieved in all dose groups, with
response rates ranging from 20% to 63%. The response rate was
not dose-dependent (dose as mg/patient, dose adjusted for body
weight (mg/kg) or dose adjusted for body surface area (mg/m2).
Best response rate across dose groups was 43% for evaluable
patients. Previous rituximab-treated patients had a response rate
across dose groups of 64%, and 3 of the responders were
previously refractory to rituximab. This might indicate a
different mode of action for ofatumumab. Sixty-five percent of
Figure 6. Ofatumumab serum concentrations in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. BLQ indicates below level of quantification. The
limit of quantification was 0.1 g/mL.
Figure 5. Kaplan-Meier estimates across dose groups of time to progression
(all patients), time to progression (responders), duration of response, and time
to next anti-FL therapy. Based on Kaplan-Meier estimates, at a median/maximum
follow-up of 9.2/38.6 months, the median TTP for all patients was 8.8 months (95%
CI, 5.4-20.0 months), the median TTP for responders was 32.6 months (95% CI,
22.4-38.6 months), and the median duration of response was 29.9 months (95% CI,
19.7-36.1 months). The median time to next anti-FL therapy was not reached during
the study period, and data were not collected after month 12. Given for a time point
where estimates could be calculated, the proportion of patients who had time to next
FL therapy more than 8.5 months was 80% (67%; 100%). All indicates 40 patients.
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evaluable patients converted to negative BCL2 status (no
detectable cells with BCL2 rearrangements) in the peripheral
blood after ofatumumb treatment. No correlation with objective
overall response was found.
Values for CL and T1/2 did not indicate dose-dependent PK
after either the first or the fourth dosing period. This was
expected as mAb’s, unlike small molecules, most often are
eliminated in a nonlinear fashion. Between the 2 periods, a
statistically significant change occurred for T1/2 and CL. Conse-
quently, the exposure to ofatumumab increased during the 4
weekly dosages beyond what could be expected from normal
accumulation as judged from the initial T1/2. After the fourth
dose, the median T1/2 across dose groups was 410 hours and CL
was 9.5 mL/hour for ofatumumab. For comparison, the mean
T1/2 of rituximab is 209 hours and CL is 9.2 mL/hour.15,19 As the
elimination process of mAb’s takes place once the antibody is
bound to the target molecule, the observed difference might
be caused by the profound B-cell depletion, which occurs
already after the initial infusion, leaving a minimal number of
circulating B cells available for binding to ofatumumab. A
correlation between exposure (AUC) and response to treatment
was not found.
Because ofatumumab is a fully human antibody, immunogenic-
ity was not expected to pose a problem. In this first in human trial,
only one patient had a transient borderline (8-fold) titer increase at
week 12.
In conclusion, treatment with ofatumumab was found to be
well tolerated in patients with relapsed or refractory FL grade 1
or 2 in doses up to 1000 mg. In addition, preliminary data on
lymphoma response are encouraging. These results warrant
further exploration of ofatumumab’s potential in the treatment
of FL as well as other B-cell malignancies with low CD20 and
high CD55 and CD59 expression, such as B-CLL. Indeed,
ofatumumab has been shown to induce significant clinical
responses in relapsed CLL.20 For the subsequent trial in
rituximab-refractory FL patients, a low (500-mg) versus a high
(1000-mg) dose of ofatumumab was selected to be explored
(www.clinicaltrials.gov; #NCT00394836).
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